Analysis of Exhaled Breath From Patients With Lung-/Airway Diseases (BigExBrESs) (BigExBrESs)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Malcolm Kohler, MD
- Phone Number: +41442551111
- Email: malcolm.kohler@usz.ch
Study Contact Backup
- Name: Noriane Sievi, MSc
- Phone Number: +41442559815
- Email: noriane.sievi@usz.ch
Study Locations
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Switzerland, 8091
- Recruiting
- University Hospital Zurich
-
Contact:
- Malcolm Kohler, MD
- Phone Number: +41442551111
- Email: malcolm.kohler@usz.ch
-
Contact:
- Noriane Sievi, MSc
- Phone Number: +41442559815
- Email: noriane.sievi@usz.ch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed informed consent
- Age ≥ 18 years at study entry
Exclusion Criteria:
- Physical or intellectual impairment precluding informed consent or protocol adherence
- Known pregnancy
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Lung-/Airway diseases
Patients with lung-/airway diseases
|
no intervention
|
|
Controls
Participants without lung-/airway disease
|
no intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Molecular breath pattern
Time Frame: at baseline
|
Comparison of molecular weights of breath features from patients with different respiratory diseases
|
at baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in molecular breath pattern
Time Frame: over one year
|
Change in the molecular breath pattern during the course of the disease (untargeted approach)
|
over one year
|
|
Symptoms
Time Frame: at baseline
|
Correlation/Association of molecular weights of specific breath features with symptoms (e.g.
dyspnea)
|
at baseline
|
|
Inflammatory markers
Time Frame: at baseline
|
Correlation/Association of molecular weights of specific breath features with inflammatory markers (e.g.
eosinophils)
|
at baseline
|
|
Controls
Time Frame: at baseline
|
Differentiation of molecular breath pattern (m/z ratios of molecules in exhaled breath) between diseased patients and participants without respiratory disease (untargeted approach)
|
at baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2021-00539
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.